Fidson Healthcare Plc announced a substantial 41% surge in revenue, reaching N119.06 billion for the fiscal year 2025. This impressive growth was primarily fueled by a 41.5% increase in sales from its ethical drug segment, which generated N77.8 billion.
The company disclosed these figures in its audited financial statements for the year ending December 31, 2025. The strong performance indicates robust demand across Fidson's product range, even as the company navigated a challenging operating environment characterized by rising costs.
Profitability saw a marked improvement, with profit before tax climbing by 94% to N14.96 billion, up from N7.7 billion in the previous year. This demonstrates the resilience of Fidson’s core operations despite prevailing macroeconomic pressures.
The growth in ethical drug sales, which rose from N55.0 billion in 2024, was a key driver for the company's topline expansion.
Fidson’s strong earnings performance was achieved amidst notable cost pressures. The company's financials reveal an increase in financing and tax obligations, which partially offset the gains from revenue expansion.
Specifically, finance costs increased by approximately 30% to N7.13 billion. This rise is attributed to higher borrowing costs, including commercial paper issuances at rates exceeding 23%.
The company also recorded a net foreign exchange loss of N6.01 billion, highlighting its exposure to currency volatility due to a reliance on imported raw materials.
Tax expenses saw a sharp increase of over 80%, amounting to N4.25 billion. While finance income grew by 140% to N144 million, this provided only a modest offset to the escalating operational costs.
Overall, the financial data indicates that while revenue and profit expanded significantly, pharmaceutical firms dependent on imports faced a demanding cost environment.
Beyond revenue and profit growth, Fidson’s balance sheet and cost structure offer deeper insights into its financial standing. The company made notable adjustments to its debt profile while managing rising operational expenses.
Interest-bearing loans declined by 48.7% to N3.60 billion. However, the current portion of loans increased, suggesting short-term borrowing needs.
